Customers line up for last 'gyudon' at Yoshinoya outlets

Customers line up for last 'gyudon' at Yoshinoya outlets

TOKYO, Japan - Customers line up for ''gyudon'' beef-on-rice dishes at a Tokyo outlet of fast food chain Yoshinoya D&C Co. Feb. 10, the day before it is to halt serving the popular dish at most shops because stocks are depleted following Japan's import ban on U.S. beef.

  • Product Code
  • ILEA001101196
  • Registered date
  • 2004/2/10 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2004 Kyodo News
  • Media size
  • 1864 × 1178 pixel
  • Resolution
  • dpi
  • Deployment size
  • 634.61(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Rice ball shop in Paris

    Rice ball shop in Paris

    Photo taken Feb. 9, 2024, shows an outlet in Paris of Omusubi Gonbei, a Japanese chain of rice ball shops. Rice balls, called onigiri or omusubi in Japanese, are gaining popularity as a healthy food in the French capital.
      Seibu Ikebukuro workers strike

      Seibu Ikebukuro workers strike

      Striking workers represented by a labor union at Japanese department store operator Sogo & Seibu Co. march in the streets of Tokyo's Toshima Ward on Aug. 31, 2023. Store workers are opposing plans by parent Seven & i Holdings Co. to sell the 10-store chain to a U.S.-based investment fund.
        Seibu Ikebukuro workers strike

        Seibu Ikebukuro workers strike

        Photo taken on Aug. 31, 2023, shows the Seibu Ikebukuro department store in Tokyo's Toshima Ward. Store workers staged a strike the same day, opposing plans by parent Seven & i Holdings Co. to sell the 10-store Sogo & Seibu chain to a U.S.-based investment fund.
          Seibu department workers strike

          Seibu department workers strike

          A pedestrian passes by the shuttered flagship Seibu department store in Tokyo's Ikebukuro area on Aug. 31, 2023, amid a labor strike against parent Seven & i Holdings Co.'s planned sale of the 10-store Sogo & Seibu chain to a U.S.-based investment fund.
            Transport ministry inspects Bigmotor offices over alleged fraud

            Transport ministry inspects Bigmotor offices over alleged fraud

            Officials of Japan's transport ministry conduct an on-site inspection of a Bigmotor Co. outlet in Nagoya, central Japan, on July 28, 2023, amid allegations that the used car dealership chain charged excessive repair fees after intentionally damaging cars and made fraudulent insurance claims. The ministry raided 33 other Bigmotor outlets in 24 prefectures the same day.
              Transport ministry inspects Bigmotor offices over alleged fraud

              Transport ministry inspects Bigmotor offices over alleged fraud

              Officials of Japan's transport ministry conduct an on-site inspection of a Bigmotor Co. outlet in Nagoya, central Japan, on July 28, 2023, amid allegations that the used car dealership chain charged excessive repair fees after intentionally damaging cars and made fraudulent insurance claims. The ministry raided 33 other Bigmotor outlets in 24 prefectures the same day.
                Food delivery robot

                Food delivery robot

                A food delivery robot enters an elevator to deliver lunch, snacks and other food in an office building in Tokyo during a media demonstration on Jan. 10, 2023, held a day ahead of a 17-day test operation by East Japan Railway Co. and KDDI Corp.
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.